Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKA Rabies Vaccine Accelerated Regimen Phase II
NCT02956421Phase 2Completed
- Sponsor
- LakeShore Biopharma Co., Ltd
- Start
- Feb 2016
- Primary completion
- Oct 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PIKA rabies vaccine in rabies (2 arms), sponsored by LakeShore Biopharma Co., Ltd. Primary endpoints: Rabies Virus Neutralizing Antibody Titer at 42 days and Adverse Events at 42 days. Started Feb 2016; status: completed.
02
Drugs
PIKA rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02956421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956421.